Cancer Res February 15 2011 71 (4) 1201-1202;
This study identifies a long sought tubulin tyrosine carboxypeptidase and its tumor suppressor inhibitor with important implications for microtubule-targeted cancer therapeutics.
Findings offer an important advance in understanding the control of anoikis, an adhesion deprival-induced form of apoptosis that is generally important in cancer biology.
An immune cell regulatory molecule implicated in immune escape is often overexpressed in solid tumor cells, where it also promotes epithelial-mesenchymal transition, hinting at intriguing links between these two hallmarks of cancer progression.
HIF-1α exerts a critical role in malignant progression through a novel pathway characterized in this study, potentially explaining the common overexpression of HIF-1α in aggressive cancers.
Findings promote understanding of how cancer vaccines can trigger tumor rejection responses in humans.
Results define roles for T cell subpopulations that infiltrate human colorectal cancers, offering opportunities to improve clinical prognosis and treatment decisions.
Interactions between stromal fibroblasts with different capacities to respond to TGFβ contribute to a microenvironment which can promote malignant progression.
Findings identify a phosphoinositide-generating enzyme as a direct trigger for nuclear translocation of β-catenin, which promotes a central pathway of oncogenic gene expression and tumorigenesis.
This important study reveals an essential intermediary transcription factor linking TGFβ1 signaling to E-cadherin control in regulation of the epithelial-mesenchyme transition, a critical determinant of the metastatic potential in many types of carcinoma.
Findings connect a transcriptional repressor of the AML/ETO family involved in leukemia to a requirement for efficient inflammatory carcinogenesis in the colon.
A family of microRNAs with tumor suppressor function in prostate cancer targets a master class of regulators of chromatin organization and cell growth that regulate the prognostic factor prostate specific antigen.
Findings suggest that Toll receptor signaling to NF-kB during tissue infection or inflammation may drive progression of premalignant prostatic lesions and prostate cancers that involve the commonly activated fusion oncogene TMPRSS2/ERG.
Important mechanistic findings reveal the RKIP/GSK3 signaling axis as a potential theranostic target for addressing cancer progression.
Results from this large consortium study broaden the significance of a chromosomal marker associated with breast cancer risk in women of diverse ancestry.
Findings identify a lung cancer risk variant of genome-wide significance that is independent of smoking quantity and distinct from TP53BP1 coding variants.
Findings offer mechanistic and pharmacologic information that significantly advances understanding of the biology and therapeutic utility of ALK1 antibodies for cancer treatment.
CD47 is an independent prognostic factor and represents a novel therapeutic antibody target for the treatment of human acute lymphoblastic leukemia.
Findings identify kinases that regulate growth and survival of neuroblastoma tumor-initiating cells, highlighting PLK1 as an attractive therapeutic target for treating advanced neuroblastoma.
Extensive preclinical study of a novel dual-targeted small molecule inhibitor of VEGF and FGF receptors reveal striking anti-angiogenic and anti-tumor effects that warrant clinical evaluation.
Alterations in anti-apoptotic cell signaling dynamics, rather than loss of peptide and/or MHC complex, represent the major mechanism by which melanomas escape tumor-specific T cells.
This study offers preclinical proof-of-concept that drug-like small molecule inhibitors of RNA polymerase I could offer a widely applicable strategy to treat human cancer.
Non-cytotoxic mesenchymal to epithelial differentiation therapy for renal cell cancer is a mechanistically distinct therapeutic approach with potentially unique advantages.
An anti-metastatic microRNA is defined with an initial preclinical proof of concept for its possible use in blocking dissemination of metastatic gastric cancers.
This preclinical study illustrates how combining multiple genetic and antibody targeting principles into a single nanobiopolymer system can provide an effective strategy to treat cancer.
Findings offer an in vivo genetic proof that Fes provides an essential support to breast cancer growth and metastasis through action in vascular endothelial and myeloid cells in the tumor microenvironment.
Vascular mimicry, a mechanism evolved by melanomas as a strategy to gain a blood supply, is regulated by melanoma stem-like cells that express the well established angiogenic receptor VEGFR-1.
Findings suggest how the androgen receptor may continue to drive prostate cancer growth in patients treated with androgen deprivation therapy, despite low circulating levels of testicular androgens, with implications for therapeutic improvements.
Transcriptome changes in epithelial/macrophage cell fusion hybrids that can occur in cancer may provide a pathophysiological foundation for metastatic progression.